health
Camupepimut misses primary endpoint in phase 2 pancreatic cancer trial
In the randomized AMPLIFY-7P phase 2 trial, camupepimut did not significantly improve disease-free survival across all participants after pancreatic cancer surgery. Prespecified subgroup analyses and immune-response findings provide signals for testing in a larger trial.